A potential new target for asthma therapy: A Disintegrin and Metalloprotease 10 (ADAM10) involvement in murine experimental asthma

J. A. Mathews, J. Ford, S. Norton, D. Kang, A. Dellinger, D. R. Gibb, A. Q. Ford, H. Massay, C. L. Kepley, P. Scherle, A. D. Keegan, D. H. Conrad

Research output: Contribution to journalArticle

Abstract

Background: Elevated levels of CD23, a natural regulator of IgE production, have been shown to decrease the signs of lung inflammation in mice. The aim of this study was to study the involvement of ADAM10, the primary CD23 sheddase, in experimental asthma. Methods: ADAM10 was blocked either by using mice with a B-cell-specific deletion of the protease or pharmacologically by intranasal administration of selective ADAM10 inhibitors. Airway hypersensitivity (AHR) and bronchoaveolar lavage fluid (BALF) eosinophilia and select BALF cytokine/chemokine levels were then determined. Results: Using an IgE and mast cell-dependent mouse model, B-cell-specific ADAM10 -/- mice (C57B/6 background) exhibited decreased eosinophilia and AHR when compared with littermate (LM) controls. Treatment of C57B/6 mice with selective inhibitors of ADAM10 resulted in an even further decrease in BALF eosinophilia, as compared with the ADAM10 -/- animals. Even in the Th2 selective strain, Balb/c, BALF eosinophilia was reduced from 60% to 23% respectively. In contrast, when an IgE/mast cell-independent model of lung inflammation was used, the B-cell ADAM10 -/- animals and ADAM10 inhibitor treated animals had lung inflammation levels that were similar to the controls. Conclusions: These results thus show that ADAM10 is important in the progression of IgE-dependent lung inflammation. The use of the inhibitor further suggested that ADAM10 was important for maintaining Th2 levels in the lung. These results thus suggest that decreasing ADAM10 activity could be beneficial in controlling asthma and possibly other IgE-dependent diseases.

Original languageEnglish (US)
Pages (from-to)1193-1200
Number of pages8
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume66
Issue number9
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Disintegrins
Metalloproteases
Asthma
Immunoglobulin E
Therapeutic Irrigation
Eosinophilia
Pneumonia
Therapeutics
B-Lymphocytes
Mast Cells
Hypersensitivity
Intranasal Administration
Chemokines
Peptide Hydrolases

Keywords

  • ADAM10
  • asthma
  • CD23
  • IgE
  • Th2

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

A potential new target for asthma therapy : A Disintegrin and Metalloprotease 10 (ADAM10) involvement in murine experimental asthma. / Mathews, J. A.; Ford, J.; Norton, S.; Kang, D.; Dellinger, A.; Gibb, D. R.; Ford, A. Q.; Massay, H.; Kepley, C. L.; Scherle, P.; Keegan, A. D.; Conrad, D. H.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 66, No. 9, 09.2011, p. 1193-1200.

Research output: Contribution to journalArticle

Mathews, JA, Ford, J, Norton, S, Kang, D, Dellinger, A, Gibb, DR, Ford, AQ, Massay, H, Kepley, CL, Scherle, P, Keegan, AD & Conrad, DH 2011, 'A potential new target for asthma therapy: A Disintegrin and Metalloprotease 10 (ADAM10) involvement in murine experimental asthma', Allergy: European Journal of Allergy and Clinical Immunology, vol. 66, no. 9, pp. 1193-1200. https://doi.org/10.1111/j.1398-9995.2011.02614.x
Mathews, J. A. ; Ford, J. ; Norton, S. ; Kang, D. ; Dellinger, A. ; Gibb, D. R. ; Ford, A. Q. ; Massay, H. ; Kepley, C. L. ; Scherle, P. ; Keegan, A. D. ; Conrad, D. H. / A potential new target for asthma therapy : A Disintegrin and Metalloprotease 10 (ADAM10) involvement in murine experimental asthma. In: Allergy: European Journal of Allergy and Clinical Immunology. 2011 ; Vol. 66, No. 9. pp. 1193-1200.
@article{391ec21d9f3e47b4bf92f0b285cb2c93,
title = "A potential new target for asthma therapy: A Disintegrin and Metalloprotease 10 (ADAM10) involvement in murine experimental asthma",
abstract = "Background: Elevated levels of CD23, a natural regulator of IgE production, have been shown to decrease the signs of lung inflammation in mice. The aim of this study was to study the involvement of ADAM10, the primary CD23 sheddase, in experimental asthma. Methods: ADAM10 was blocked either by using mice with a B-cell-specific deletion of the protease or pharmacologically by intranasal administration of selective ADAM10 inhibitors. Airway hypersensitivity (AHR) and bronchoaveolar lavage fluid (BALF) eosinophilia and select BALF cytokine/chemokine levels were then determined. Results: Using an IgE and mast cell-dependent mouse model, B-cell-specific ADAM10 -/- mice (C57B/6 background) exhibited decreased eosinophilia and AHR when compared with littermate (LM) controls. Treatment of C57B/6 mice with selective inhibitors of ADAM10 resulted in an even further decrease in BALF eosinophilia, as compared with the ADAM10 -/- animals. Even in the Th2 selective strain, Balb/c, BALF eosinophilia was reduced from 60{\%} to 23{\%} respectively. In contrast, when an IgE/mast cell-independent model of lung inflammation was used, the B-cell ADAM10 -/- animals and ADAM10 inhibitor treated animals had lung inflammation levels that were similar to the controls. Conclusions: These results thus show that ADAM10 is important in the progression of IgE-dependent lung inflammation. The use of the inhibitor further suggested that ADAM10 was important for maintaining Th2 levels in the lung. These results thus suggest that decreasing ADAM10 activity could be beneficial in controlling asthma and possibly other IgE-dependent diseases.",
keywords = "ADAM10, asthma, CD23, IgE, Th2",
author = "Mathews, {J. A.} and J. Ford and S. Norton and D. Kang and A. Dellinger and Gibb, {D. R.} and Ford, {A. Q.} and H. Massay and Kepley, {C. L.} and P. Scherle and Keegan, {A. D.} and Conrad, {D. H.}",
year = "2011",
month = "9",
doi = "10.1111/j.1398-9995.2011.02614.x",
language = "English (US)",
volume = "66",
pages = "1193--1200",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - A potential new target for asthma therapy

T2 - A Disintegrin and Metalloprotease 10 (ADAM10) involvement in murine experimental asthma

AU - Mathews, J. A.

AU - Ford, J.

AU - Norton, S.

AU - Kang, D.

AU - Dellinger, A.

AU - Gibb, D. R.

AU - Ford, A. Q.

AU - Massay, H.

AU - Kepley, C. L.

AU - Scherle, P.

AU - Keegan, A. D.

AU - Conrad, D. H.

PY - 2011/9

Y1 - 2011/9

N2 - Background: Elevated levels of CD23, a natural regulator of IgE production, have been shown to decrease the signs of lung inflammation in mice. The aim of this study was to study the involvement of ADAM10, the primary CD23 sheddase, in experimental asthma. Methods: ADAM10 was blocked either by using mice with a B-cell-specific deletion of the protease or pharmacologically by intranasal administration of selective ADAM10 inhibitors. Airway hypersensitivity (AHR) and bronchoaveolar lavage fluid (BALF) eosinophilia and select BALF cytokine/chemokine levels were then determined. Results: Using an IgE and mast cell-dependent mouse model, B-cell-specific ADAM10 -/- mice (C57B/6 background) exhibited decreased eosinophilia and AHR when compared with littermate (LM) controls. Treatment of C57B/6 mice with selective inhibitors of ADAM10 resulted in an even further decrease in BALF eosinophilia, as compared with the ADAM10 -/- animals. Even in the Th2 selective strain, Balb/c, BALF eosinophilia was reduced from 60% to 23% respectively. In contrast, when an IgE/mast cell-independent model of lung inflammation was used, the B-cell ADAM10 -/- animals and ADAM10 inhibitor treated animals had lung inflammation levels that were similar to the controls. Conclusions: These results thus show that ADAM10 is important in the progression of IgE-dependent lung inflammation. The use of the inhibitor further suggested that ADAM10 was important for maintaining Th2 levels in the lung. These results thus suggest that decreasing ADAM10 activity could be beneficial in controlling asthma and possibly other IgE-dependent diseases.

AB - Background: Elevated levels of CD23, a natural regulator of IgE production, have been shown to decrease the signs of lung inflammation in mice. The aim of this study was to study the involvement of ADAM10, the primary CD23 sheddase, in experimental asthma. Methods: ADAM10 was blocked either by using mice with a B-cell-specific deletion of the protease or pharmacologically by intranasal administration of selective ADAM10 inhibitors. Airway hypersensitivity (AHR) and bronchoaveolar lavage fluid (BALF) eosinophilia and select BALF cytokine/chemokine levels were then determined. Results: Using an IgE and mast cell-dependent mouse model, B-cell-specific ADAM10 -/- mice (C57B/6 background) exhibited decreased eosinophilia and AHR when compared with littermate (LM) controls. Treatment of C57B/6 mice with selective inhibitors of ADAM10 resulted in an even further decrease in BALF eosinophilia, as compared with the ADAM10 -/- animals. Even in the Th2 selective strain, Balb/c, BALF eosinophilia was reduced from 60% to 23% respectively. In contrast, when an IgE/mast cell-independent model of lung inflammation was used, the B-cell ADAM10 -/- animals and ADAM10 inhibitor treated animals had lung inflammation levels that were similar to the controls. Conclusions: These results thus show that ADAM10 is important in the progression of IgE-dependent lung inflammation. The use of the inhibitor further suggested that ADAM10 was important for maintaining Th2 levels in the lung. These results thus suggest that decreasing ADAM10 activity could be beneficial in controlling asthma and possibly other IgE-dependent diseases.

KW - ADAM10

KW - asthma

KW - CD23

KW - IgE

KW - Th2

UR - http://www.scopus.com/inward/record.url?scp=79961128320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961128320&partnerID=8YFLogxK

U2 - 10.1111/j.1398-9995.2011.02614.x

DO - 10.1111/j.1398-9995.2011.02614.x

M3 - Article

C2 - 21557750

AN - SCOPUS:79961128320

VL - 66

SP - 1193

EP - 1200

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 9

ER -